Cholesteatoma is a rare but serious condition where an abnormal collection of skin cells forms in the middle ear, often as a result of chronic ear infections or poor eustachian tube function.^[1] Cholesteatomas are classified into two main types: congenital and acquired. Congenital cholesteatomas are uncommon (4%–24% of cholesteatomas overall), develop in children and are typically found incidentally as a white mass behind an intact eardrum.^[2–4] Acquired cholesteatomas are more prevalent and develop later in life. They predominantly arise from chronic suppurative otitis media (CSOM), characterized by persistent ear discharge (otorrhea). They can be further categorized into those associated with a retraction pocket (primary acquired cholesteatoma) or those associated with a perforation (secondary acquired cholesteatoma). Acquired cholesteatomas can be characterized based on their sites of origin as either pars flaccida (about 80% of cases) or pars tensa (approximately 20% of cases), which can erode local structures if left untreated.^[5]

Diagnosing cholesteatoma requires ruling out other conditions that might cause similar symptoms, such as chronic otitis media, tympanic membrane retraction without cholesteatoma, and tumors in the ear or temporal bone.^[6]

Thus, the diagnosis of cholesteatoma involves a combination of clinical evaluation, imaging studies, and, in some cases, audiometric testing. Treatment is always surgical and post-operative follow-up is necessary. Here is an overview of the diagnostic process, treatment, and follow-up of these patients.

An intriguing case is an 8-year-old boy who had undergone a thorough examination elsewhere. Otomicroscopy revealed a white mass beneath an intact eardrum in the left ear. Nevertheless, in the absence of tympanic perforation, otorrhea, and hearing loss, the physicians thought it was tympanic sclerosis(Fig. 2) . A CT scan of the temporal bone revealed a mass in the left middle ear and mastoid. However, it could not ascertain if it was a congenital cholesteatoma(Fig. 3) .

An MRI scan subsequently revealed fluid in the mastoid bone, but it could not confirm the presence of a cholesteatoma(Fig. 4) . Conversely, non-EP DW-MRI revealed a small cholesteatoma (4 mm) in the left middle ear(Fig. 5) . The absence of perforation, together with this finding, indicated the diagnosis of congenital cholesteatoma. This case underscores the significance of DWI in initial diagnosis, since only DW-MRI facilitated the identification of congenital cholesteatoma.

Residual cholesteatomas can occur from incomplete removal of the cholesteatoma matrix during surgery, often because of the complex anatomy of the middle ear and mastoid. Non-EP DW-MRI can detect these residual lesions early, preventing further complications like hearing loss or the need for additional extensive surgery. Although, even after complete removal, cholesteatomas can recur. Recurrent cholesteatoma results from the reformation of a retraction pocket. Non-EP DW-MRI is highly effective in identifying these recurrences months or years after the initial surgery. Cholesteatomas typically need time to regrow (2.7–4 mm per year) and reach a size detectable on imaging, so non-EP DW-MRI is usually performed 12 months postoperatively, and then periodically thereafter for at least 5 years.^[16]

While CT is excellent for evaluating bony erosion caused by cholesteatoma, it cannot reliably differentiate cholesteatoma from other soft tissue masses or postoperative changes, like scar tissue. Non-EP DW-MRI, however, is specifically sensitive to the restricted diffusion characteristics of cholesteatoma, making it more accurate for detecting residual disease. Traditional MRI, even with contrast, is less sensitive for small cholesteatomas. EP-DWI, though useful, is often plagued by distortion artifacts due to the nearby air-bone interfaces in the middle ear, making non-EP DW-MRI the preferred technique due to its reduced artifact profile and higher diagnostic accuracy.^[17]

The clinical utility of non-EP DW-MRI is great. Before the advent of non-EP DW-MRI, patients usually underwent routine second-look surgery (a second operation to ensure that all cholesteatoma tissue had been removed). Non-EP DW-MRI has reduced the need for these invasive procedures by providing a non-invasive, reliable way to check for residual disease. Also it improves surgical planning.^[18] When residual or recurrent disease is detected, non-EP DW-MRI helps in precisely localizing the cholesteatoma, aiding in better pre-surgical planning for any necessary reoperation. Furthermore, non-EP DW-MRI is typically performed between 12 and 18 months after surgery, depending on the patient’s clinical course. If no disease is found, repeat imaging is done periodically (e.g., in 3 and 5 years), allowing for early detection of any recurrence.^[19]

Undoubtedly there are limitations to its use. While non-EP DW-MRI is highly sensitive, very small cholesteatomas (less than 3 mm) may still escape detection. Repetition of the examination after time can overcome this problem. Furthermore, close clinical follow-up remains essential in patients at high risk for recurrence. Also, non-EP DW-MRI is not universally available and the technology may be more expensive than other imaging modalities. However, its high sensitivity and specificity make it a cost-effective tool in the long run by reducing the need for unnecessary surgeries.^[20]

Diagnosing cholesteatoma involves a combination of careful history-taking, clinical examination (otoscopy), imaging (mainly CT scans), and, if necessary, hearing tests or surgery for confirmation. Early detection is crucial to prevent complications, such as hearing loss, facial nerve damage, or even the spread of infection to the brain. Non-EP DW-MRI is a valuable tool in the follow-up of patients with cholesteatoma, offering high sensitivity and specificity for detecting residual or recurrent disease and also, in initial diagnosis of congenital cholesteatomas. By minimizing artifacts and providing better image resolution than echoplanar DWI, it significantly reduces the need for second-look surgeries and helps in early identification of disease, ensuring better outcomes for patients.

The authors have no funding to report.

The authors do not report any financial or personal connections with other persons or organizations, which might negatively affect the contents of this publication and/or claim authorship rights to this publication.

Conceptualization: A.L. and G.P.; methodology: A.L. and G.P.; formal analysis: A.L.; data curation: A.L. and G.P.; writing—original draft preparation: A.L.; writing—review and editing: A.L., M.B., and D.S.; supervision: A.L. and G.P.